Credited with transforming the Indian bulk drug industry from importdependence to an export-oriented industry, Dr Reddy’s Laboratories was the first company in India to embark on drug discovery programmes. India, USA, Russia, CIS (Commonwealth Independent States), Germany and UK are its biggest markets. Crossing the `5013 crore (US $1 billion) revenue mark in record time to become India’s fastest-growing pharmaceutical company, the company launched 135 new generic products, filed 107 new product registrations and filed 56 DMFs globally during 2011.
Dr Reddy’s Laboratories Ltd is an integrated global pharmaceutical company headquartered in Hyderabad. It is committed to providing affordable and innovative medicines for healthier lives. The company employs over 14500 people globally, and through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics, and Proprietary Products – offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and New Chemical Entities. Its therapeutic focus areas include gastro-intestinal, cardiovascular, diabetology, oncology, pain management, antiinfective and pediatrics. Dr Reddy’s Laboratories posted revenues of `7469 crore (US $1.5 billion approximately) and a net profit of `108 crore (US $211 million approximately), at the end of 2011.
Founded by Dr Kallam Anji Reddy in 1984, Dr Reddy’s Laboratories went public two years later, listing on the BSE. It is also the first Asia Pacific pharmaceutical company outside of Japan to list on the New York Stock Exchange.
Dr Reddy’s has 18 manufacturing facilities, of which 14 are in India, and the rest overseas.
In 1990, it became the first Indian pharmaceutical company to export the drugs Norfloxacin and Ciprofloxacin to Europe and the Far East. The following year, the company launched Omez, its own brand of antacid drug Omeprazole, and the first brand of Omeprazole to enter the Indian market. It went on to become Dr Reddy’s first `100 crore (US $20 million approximately) brand, and the leading brand of Omeprazole in 11 countries worldwide.
Dr Reddy’s Research Foundation (DRF), established in 1993, discovered a potent glitazone drug, used to treat Type 2 diabetes mellitus, and licensed it to Novo Nordisk A/S of Denmark, the world leader in diabetes care. With this, Dr Reddy’s became the first Indian pharmaceutical company to outlicense an original molecule. In 1994, the company filed an Abbreviated New Drug Application (ANDA) with the United States Food and Drug Administration for Ranitidine, used to treat peptic ulcers.
From 1999 to 2008, Dr Reddy’s embarked on an aggressive expansion plan, acquiring American Remedies Ltd (ARL); BMS Laboratories Ltd; Meridian Healthcare (UK) Ltd, a wholly owned subsidiary of BMS Laboratories; Roche’s API business in Cuernavaca, Mexico; Betapharm, the fourthlargest generic pharmaceuticals company in Germany; BASF’s pharmaceutical contract manufacturing business in Shreveport, Louisiana; and a portion of Dow Pharma’s small molecules business. During this period, Dr Reddy’s launched Reditux – the world’s first monoclonal antibody (MAb) biosimilar used in the treatment of Non-Hodgkin’s Lymphoma.
The drug maker has 18 manufacturing facilities, of which 14 are in India, and the rest overseas. The company plans to invest a further `500 crore (US $98 million approximately) in expanding its manufacturing capacity over the course of 2012-13. It is establishing a formulation manufacturing plant in Vizag and a Biologics manufacturing facility in Hyderabad.
Dr Reddy’s Laboratories practices sustainable chemistry which is the design of chemical products and processes that reduce or eliminate the use or generation of hazardous substances. It is the world’s first generic pharmaceutical company to become a member of the Pharmaceutical Roundtable, a partnership between the American Chemical Society Green Chemistry Institute and global pharmaceutical companies that “promotes innovation while catalysing the integration of green chemistry and green engineering in the pharmaceutical industry.”
The company is also committed to philanthropy in the areas of patient care, education and livelihood creation. Its Livelihood Advancement Business School (LABS), the flagship programme of Dr Reddy’s Foundation for Human and Social Development creates, implements and disseminates sustainable and replicable livelihood models directly through partnerships for weaker sections of society. Over 260000 direct livelihoods have been created till date through the livelihood Advancement Business School (LABS) programme. Through its education efforts Dr Reddy’s Foundation provides learning opportunities for those who have never been to school, or are dropouts, while improving quality of education across schools.
Dr Reddy’s Foundation for Health Education aims to create professionals (health educators) who work with the medical fraternity to offer an integrated, multi-disciplinary approach to good health. The programmes also aim at building the necessary soft skill capabilities with the objective of strengthening the healthcare delivery system for better patient care.
Pharmexcil Award (Gold Prize) for Export Excellence for Outstanding Export Performance in the Large Scale Industry category, 2011
Americares Spirit of Humanity Award for Best CSR by a Pharmaceutical Company, 2011
Thomson Reuters Innovation Award - India for PharmaCorporate, 2011
NDTV Profit Business Leadership Awards for Business Leader in the Pharmaceutical Sector, 2010
Forbes 2010 Asia Fab 50 companies’ list, 2010
ICT Platinum Award from the Institute of Chemical Technology, Pune, 2009
Corporate Citizen of the Year 2007-08 Award for Corporate Excellence from The Economic Times, 2008